Drugs Made In America Acquisition Corp. DMAA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 6.10M | 6.66M | 5.94M | 5.45M | -- |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.64M | -7.21M | -6.62M | -6.31M | -- |
| Change in Net Operating Assets | 32.00K | 175.90K | 138.90K | 323.00K | -- |
| Cash from Operations | -517.20K | -379.30K | -539.20K | -537.20K | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 98.71M | 0.00 | -231.15M | -231.15M | -- |
| Cash from Investing | 98.71M | 0.00 | -231.15M | -231.15M | -- |
| Total Debt Issued | 350.00K | 100.00K | -- | 1.39M | -- |
| Total Debt Repaid | -99.31M | 0.00 | -900.00K | -1.93M | -- |
| Issuance of Common Stock | 186.60K | 293.20K | 232.59M | 232.49M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 600.00K | 0.00 | 3.20K | -257.20K | -- |
| Cash from Financing | -98.17M | 393.20K | 231.69M | 231.69M | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 19.50K | 14.00K | 4.80K | -400.00 | -- |